In recent trading session, Sangamo Therapeutics Inc (NASDAQ:SGMO) saw 1.61 million shares changing hands at last check today with its beta currently measuring 1.47. Company’s recent per share price level of $1.14 trading at $0.04 or 3.64% at last check today assigns it a market valuation of $237.86M. That most recent trading price of SGMO’s stock is at a discount of -178.95% from its 52-week high price of $3.18 and is indicating a premium of 73.68% from its 52-week low price of $0.30.

For Sangamo Therapeutics Inc (SGMO), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.88. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.

Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information

Upright in the green today for gaining 3.64%, in the last five days SGMO remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $1.14 price level, adding 7.94% to its value on the day. Sangamo Therapeutics Inc’s shares saw a change of 11.76% in year-to-date performance and have moved 0.88% in past 5-day. Sangamo Therapeutics Inc (NASDAQ:SGMO) showed a performance of 0.88% in past 30-days.

Wall Street analysts have assigned a consensus price target of 2.5 to the stock, which implies a rise of 54.4% to its recent value today. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 3. It follows that stock’s current price would drop -75.44% in reaching the projected high whereas dropping to the targeted low would mean a loss of -75.44% for stock’s current value.

Sangamo Therapeutics Inc (SGMO) estimates and forecasts

This year revenue growth is estimated to fall -64.54% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.7M for the same. And 3 analysts are in estimates of company making revenue of 30.67M in the next quarter. Company posted 2.04M and 481k of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -15.96% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 68.41% while estimates for its earnings growth in next 5 years are of 43.70%.

Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders

WASATCH ADVISORS LP is the top institutional holder at SGMO for having 20.09 million shares of worth $7.2 million. And as of 2024-06-30, it was holding 9.8509 of the company’s outstanding shares.

The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 14.06 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.7963 of outstanding shares, having a total worth of $5.04 million.

On the other hand, Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 5.79 shares of worth $6.57 million or 2.78% of the total outstanding shares. The later fund manager was in possession of 5.65 shares on Sep 30, 2024, making its stake of worth around $6.41 million in the company or a holder of 2.71% of company’s stock.